Drugs for treating myocardial fibrosis

Zhanhong Ren; Zixuan Zhang; Li Ling; Xiufen Liu; Xin Wang

doi:10.3389/fphar.2023.1221881

Drugs for treating myocardial fibrosis

Front Pharmacol. 2023 Sep 12:14:1221881. doi: 10.3389/fphar.2023.1221881. eCollection 2023.

Authors

Zhanhong Ren^#¹, Zixuan Zhang^#^{1

2}, Li Ling¹, Xiufen Liu¹, Xin Wang³

Affiliations

¹ Hubei Key Laboratory of Diabetes and Angiopathy, Medicine Research Institute, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
² School of Basic Medical Sciences, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
³ School of Mathematics and Statistics, Hubei University of Science and Technology, Xianning, China.

^# Contributed equally.

Abstract

Myocardial fibrosis, which is a common pathological manifestation of many cardiovascular diseases, is characterized by excessive proliferation, collagen deposition and abnormal distribution of extracellular matrix fibroblasts. In clinical practice, modern medicines, such as diuretic and β receptor blockers, and traditional Chinese medicines, such as salvia miltiorrhiza and safflower extract, have certain therapeutic effects on myocardial fibrosis. We reviewed some representative modern medicines and traditional Chinese medicines (TCMs) and their related molecular mechanisms for the treatment of myocardial fibrosis. These drugs alleviate myocardial fibrosis by affecting related signaling pathways and inhibiting myocardial fibrosis-related protein synthesis. This review will provide more references and help for the research and treatment of myocardial fibrosis.

Keywords: integrated traditional Chinese and modern medicine; mechanism; modern medicine; myocardial fibrosis; traditional Chinese medicine.

Publication types

Review

Grants and funding

This study was supported by the Natural Science Foundation of Hubei Province (Grant No. 2022CFB843), Hubei Provincial Science and Technology Plan Project (Grant No. 2021DFE025), the Xianning Science and Technology Plan Project (Grant No. 2021ZRKX024), Hubei University of Science and Technology School-level Fund (No. BK202121, and BK202220), Special Project on Diabetes and Angiopathy (No. 2022TNB04) and the Scientific Research and Innovation Team of Hubei University of Science and Technology (No. 2022T01).